TrialLeukemia2022

A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.

Arsene Mekinian et al.PubMed ↗Publisher ↗

No numbers read from the abstract.